Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
about
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltrationPharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancerAltered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancyEvaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic.Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care unitsTherapeutic drug monitoring of antimicrobials.Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infectionsAntibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patientsPopulation Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.Continuous beta-lactam infusion in critically ill patients: the clinical evidenceDosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approachApplication of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignanciesPharmacokinetic and pharmacodynamic properties of meropenem.Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery.Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review.The strategy of antibiotic use in critically ill neutropenic patientsβ-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.Carbapenem susceptibility breakpoints, clinical implications with the moving target.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function.Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.Pharmacokinetic study of meropenem in healthy beagle dogs receiving intermittent hemodialysis.Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia.Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics.
P2860
Q24620193-E3F298E7-8E4F-4E19-A35E-E3B32473E756Q26825326-2123599C-555A-47AF-8821-28E8342FA66BQ33797868-41E08591-97E6-412E-8FE7-779576CD598FQ34077003-9223B67F-0AEA-42A8-98B5-DE12BCEAF70FQ34274190-280611BA-4A63-4842-BB60-BA5C65E223CAQ34329290-E71C0099-545C-4D6B-950A-AA7BEAFD1F1CQ34632953-4C58018A-358C-4F4C-A5F5-5AD2C0462B50Q35607715-1F8F7B0B-2C36-4CE8-BD03-D75DC219033FQ35640430-39E24F7E-7B70-43B7-811A-2497F22B93A1Q35759054-C25B2A71-77AB-4545-9212-287777837DCFQ35908084-49878B80-467E-46C9-8AD7-4184F4824CCAQ35960828-B47E8903-8BAE-4354-A0F5-25E7D18E2530Q36076101-D1FDB0D7-EE83-4D55-A0F7-07F188CDE4E5Q36083619-804AB259-637A-4771-805C-D2C58C918013Q36287127-A9AF4E46-96F6-46BE-8DE7-945CFC7F05D2Q36329228-92FC223F-FD42-4F2D-9393-93010D42A5FAQ36396195-42668C5E-E2B8-4CAC-A928-C5AAF0152980Q36582692-F6660944-A153-4D7A-8FF3-96435885462DQ37072039-896D3A97-C344-49EE-9179-3643CD9A9C23Q37247125-4D0311C8-3CE8-4366-8927-E34FDE02984EQ37335840-33C9F06D-E47F-4DD9-8B3D-C48EB937BC74Q37516599-3B7C259E-6E3B-40AF-9E23-762B1B79513FQ37538609-3FD23E98-AB2D-4A54-8E6D-D3E6D403780EQ37643628-C70965C5-AA93-4DA2-82E9-EE9FC7767FE2Q37685856-74744939-714E-42C4-B05E-7B2BF417491DQ37929895-E4AE832B-670B-49D8-A750-4B0DA4196C0AQ38004063-9739E7BC-BDE0-4C8C-8A37-D1D112696D8BQ38117578-9A54A998-7808-43EE-86F0-874A6A0343DAQ38751264-9B945B39-1F9B-4346-ACE1-09DE4465ECFDQ38790740-32AB80D6-EA61-4EF1-A83E-D54CCBAB749DQ39103144-0D3A552F-3C55-48C2-91C0-FCB08911173DQ39344408-3BC44171-4186-4C95-B4B1-498175A48892Q39484436-B80B5013-1F7B-4AFF-8302-7B2C7AB8392CQ39682907-52D7F162-4220-46EB-BCB8-5FC191958CF2Q40073466-AB303F41-FBAD-4F4A-9D0C-28C238D3D215Q40092306-C89748CD-5CAF-487A-ABEC-F6FF509A8959Q40186288-122E64A1-C33E-4BBF-A3F6-F97B45BFEF86Q40206253-88ECD255-51BC-489E-B346-E3D2B9AD5A46Q40306198-03C809A1-2EE7-4A53-B51F-E482EDCEE982Q40506427-7E66E68D-DA50-4511-986F-09C758BFBA30
P2860
Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pharmacokinetics and pharmacod ...... enic patients with bacteremia.
@en
type
label
Pharmacokinetics and pharmacod ...... enic patients with bacteremia.
@en
prefLabel
Pharmacokinetics and pharmacod ...... enic patients with bacteremia.
@en
P2093
P356
P1476
Pharmacokinetics and pharmacod ...... enic patients with bacteremia.
@en
P2093
Anna Nyhlén
Daniel S Sitar
Godfrey K M Harding
J Peter Donnelly
P356
10.1345/APH.1E271
P407
P577
2004-12-14T00:00:00Z